Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
Moderna: A Generational Opportunity for Investors in 2025
07:53am, Wednesday, 19'th Feb 2025
As bad as it may look on the charts, Moderna's NASDAQ: MRNA post-COVID let-down and market reset are over. The company stock trades at rock bottom in early 2025 and presents a generational opportunity
Moderna shares move higher as investors look beyond Q4 losses to pipeline potential
02:57pm, Tuesday, 18'th Feb 2025
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares added more than 8% during Tuesday's session as investors remained optimistic about the company's long-term strategy following mixed fourth quarter earnings. T
Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges
01:44pm, Tuesday, 18'th Feb 2025
On Friday, Moderna Inc. MRNA reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from EPS income of $0.55 a year ago.
Should You Buy, Hold or Sell Moderna Stock Post Q4 Earnings Release?
10:16am, Tuesday, 18'th Feb 2025
Given the uncertainty around its revenue growth, we advise short-term investors to remain cautious when investing in MRNA stock.
A lot of concern around Moderna over next year or so, says Jefferies Michael Yee
05:07pm, Friday, 14'th Feb 2025
Michael Yee, Jefferies senior analyst, joins 'Closing Bell Overtime' to talk Moderna Q4 results.
Moderna, Inc.: Working Hard But Competition Is Working Harder
01:47pm, Friday, 14'th Feb 2025
MRNA's stock surged 4,211% during COVID-19 but has since plummeted to $31, reflecting a significant bubble and raising concerns about its future. Declining revenue and net income, driven by reduced CO
Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline
12:46pm, Friday, 14'th Feb 2025
MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue guidance.
Moderna (MRNA) Q4 2024 Earnings Call Transcript
12:07pm, Friday, 14'th Feb 2025
Moderna (NASDAQ:MRNA ) Q4 2024 Earnings Conference Call February 14, 2025 8:00 AM ET Company Participants Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive
Moderna shares rise on quarterly revenue beat despite wider-than-expected loss
12:05pm, Friday, 14'th Feb 2025
Moderna Inc (NASDAQ:MRNA, ETR:0QF) stock moved higher after the pharmaceutical firm posted mixed results for the fourth quarter. It reported a wider-than-expected loss per share of $2.91, compared to
Moderna's Q4 Loss Wider Than Expected
11:33am, Friday, 14'th Feb 2025
Moderna (MRNA 2.91%), the biotech company known for its Spikevax COVID-19 vaccine, released its fourth-quarter earnings on Feb. 14. The results revealed significant financial challenges as the market
Moderna has no 'visible path' to profitability, analyst says
11:16am, Friday, 14'th Feb 2025
Pharmaceutical giant Moderna (MRNA) released mixed fourth quarter results on Friday, posting revenue of $966 million (higher than the consensus estimate of $954 million) alongside a wider-than-expecte
Moderna Posts Wider-Than-Expected Q4 Loss, 2025 Sales Guide Disappoints
11:10am, Friday, 14'th Feb 2025
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for 2025 also came in below estimates.
MRNA Reiterates Guidance, Bird Flu Vaccine in Pipeline
08:53am, Friday, 14'th Feb 2025
Jenny Horne examines earnings figures from biotech giant Moderna (MRNA). The company reported a 4Q loss as it continues to reposition itself following monumental gains during the heights of the COVID-
Moderna (MRNA) Reports Q4 Loss, Tops Revenue Estimates
08:46am, Friday, 14'th Feb 2025
Moderna (MRNA) came out with a quarterly loss of $2.50 per share versus the Zacks Consensus Estimate of a loss of $2.69. This compares to earnings of $0.55 per share a year ago.
Moderna beats on revenue but loses more than expected as it scales down manufacturing
06:40am, Friday, 14'th Feb 2025
Moderna beat on fourth-quarter revenue but lost more than expected for the period, as the biotech company continues to slash costs and see lower demand for its Covid vaccine. It marks another quarte
